- People
- Offices
- Capabilities
back- Capabilities
- Corporate, Finance and Investments
- back
- Corporate, Finance and Investments
- Overview
- Activist Defense
- Capital Markets
- Construction and Procurement
- Corporate Governance
- Emerging Companies and Venture Capital
- Employee Benefits and Executive Compensation
- Energy and Infrastructure Projects
- Financial Restructuring
- Global Human Capital and Compliance
- Investment Funds and Asset Management
- Leveraged Finance
- Mergers and Acquisitions
- Middle East and Islamic Finance and Investment
- Private Credit & Special Situations Investing
- Private Equity
- Real Estate
- Securitization
- Tax
- Technology Transactions
- Government Matters
- back
- Government Matters
- Overview
- Antitrust
- Data, Privacy and Security
- Environmental, Health and Safety
- FDA and Life Sciences
- Government Advocacy and Public Policy
- Government Contracts
- Healthcare
- International Trade
- National Security and Corporate Espionage
- Securities Enforcement and Regulation
- Special Matters and Government Investigations
- Trial and Global Disputes
- back
- Trial and Global Disputes
- Overview
- Appellate, Constitutional and Administrative Law
- Bankruptcy and Insolvency Litigation
- Class Action Defense
- Commercial Litigation
- Construction and Engineering Disputes
- Corporate and Securities Litigation
- E-Discovery
- Intellectual Property
- International Arbitration and Litigation
- Labor and Employment
- Product Liability
- Professional Liability
- Toxic & Environmental Torts
- Industries / Issues
- back
- Industries / Issues
- Automotive, Transportation and Mobility
- Energy
- Financial Services
- Food and Beverage
- Franchise and Hospitality
- Higher Education
- Life Sciences and Healthcare
- Technology
- #MeToo
- Buy American
- COVID-19 Vaccine Rollout
- Coronavirus
- Crisis Practice
- Environmental Agenda
- Focus on Women's Health
- Special Purpose Acquisition Companies (SPACs)
- The New Administration: Enforcement and Legislative Impact
- Careers
- News & Insights
- About
- Languages
News 10 results
Cases & Deals
August 24, 2021
Arbor Pharmaceuticals to Merge with Azurity Pharmaceuticals
Cases & Deals
December 31, 2020
King & Spalding Advises on Landmark Medicare Reform Bills BENES Act and PAID Act, Both Passed By Congress
Cases & Deals
June 1, 2020
Alexion Pharmaceuticals Secures Favorable Resolution and Termination of Challenge to SOLIRIS® Patents
Cases & Deals
July 30, 2019
American Clinical Laboratory Association (ACLA) Wins Jurisdictional Decision in D.C. Circuit Court
Cases & Deals
July 20, 2016
King & Spalding Advises Jounce Therapeutics on Deal Worth Up to $2.5 Billion
Cases & Deals
March 24, 2016
King & Spalding Represents GSK on Strategic Collaboration with Miltenyi Biotec
Cases & Deals
September 17, 2015
King & Spalding Advises Nurix in $150 Million-Plus Drug Collaboration and Option Deal with Celgene
Cases & Deals
June 8, 2015
King & Spalding Team Advises Five Prime Therapeutics in $131 Million License Agreement with bluebird bio
Cases & Deals
Cases & Deals
December 5, 2014
King & Spalding Advises Arbor Pharmaceuticals in Minority-Stake Sale to KKR